Valtech’s Cardioband for Mitral Valve Repair Receives Reimbursement in Germany


February 9, 2016—Valtech Cardio, Ltd. announced that it has received German Neue Untersuchungs und Behandlungsmethoden Status 1 approval for the Cardioband mitral reconstruction system, its flagship device for addressing mitral regurgitation (MR) in heart failure patients. Neue Untersuchungs und Behandlungsmethoden approval for the procedure grants reimbursement for Cardioband therapy in 70 leading hospitals in Germany, noted the company.

According to Valtech, which is headquartered in Or Yehuda, Israel, the Cardioband system combines a reconstruction implant, similar to those used in traditional surgical annuloplasty devices, with a transfemoral, transseptal delivery system. Sutureless connection of the implant to the mitral annulus is achieved using specially designed anchors. Reshaping of the mitral annulus to eliminate mitral regurgitation is done under physiological conditions and echocardiographic guidance for optimal results. Cardioband received CE Mark approval after clinical trial results demonstrated the device is a safe and efficacious intervention option for patients with functional mitral regurgitation.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.